JSIAMA Biopharmaceuticals

JSIAMA Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer. The company leverages its proprietary antibody engineering platform to design next-generation biologics, including bispecific antibodies and antibody-drug conjugates (ADCs). Its pipeline features several candidates targeting well-validated immune checkpoints and tumor-associated antigens, with lead programs currently in Phase 2 clinical trials. JSIAMA aims to address significant unmet medical needs in oncology by providing more effective and safer treatment options for patients with various solid tumors.